Table 3.
Follow-up and anti-arrhythmic drug use.
| Monitoring | n (%) |
|---|---|
| Any Monitoring* | 167 (73%) |
| Ambulatory monitor# | 96 (42%) |
| 3 months | 59 (26%) |
| 6 months | 28 (12%) |
| 9 months | 9 (4%) |
| 12 months | 9 (4%) |
| 12-month outcome | |
| ECG recurrence | 74 (32%) |
| AAD use at 12 months | |
| None | 113 (49%) |
| Class IC | 10 (4%) |
| Class III | 107 47%) |
ECG recurrence = Electrocardiographic recurrence was defined as atrial tachycardia, atrial flutter or atrial fibrillation (AT/AF/AFL) captured on 12-lead ECG, lasting >30 seconds on ambulatory monitoring or implantable device, or requiring cardioversion. AAD = antiarrhythmic drug.
*
“Any Monitoring” includes patients with AF recurrence monitoring by device interrogation or ambulatory monitor.
#
Ambulatory monitor group includes use of 24-hour Holter monitoring, event monitors, and implantable loop recorders.